[1] Whiting DR, Guariguata L, Weil C, Shaw J , IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030,
Diabetes Res Clin Pract, 94, 2011, 311– 321.
[2] Ronald K, Hyperglycemia and Microvascular and Macrovascular Disease in Diabetes, Diabetes Care, 18(2), 1995, 258-268.
[3] Irene M S, Amanda I A, Andrew W N, David R M, Susan EM et al, Association of glycaemia with macrovascular and
microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ ,321,2000,405–412.
[4] Kreisberg RA, Diabetic dyslipidemia, Am J Cardiol, 82(12A),1998, 67U-73U.
[5] Dobiásová M, AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr
Lek, 52(1), 2006, 64-71.
[6] Elizabeth S, Josef CSH, Golden,, Frederick L, Brancati,et al, Glycemic Control and Coronary Heart Disease Risk in Persons With
and Without Diabetes.The Atherosclerosis Risk in Communities Study, Arch Intern Med, 165, 2005, 1910-1916
[7] Elizabeth S, Spyridon M, Gail B, Tejal R , Frederick L. Brancati, NR., Sherita HG, Meta-Analysis: Glycosylated Hemoglobin and
Cardiovascular Disease in Diabetes Mellitus, Ann Intern Med 141(6), 2004, 421-431.
[8] Woodward A, Wallymahmed M, Wilding J, Gill G, Improved glycemic control: an unintended benefit of a nurse-led
cardiovascular risk reduction clinic. Diabet Med, 22, 2005, 1272–1274.
[9] Nakamura K, Yamagishi SI, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T, Elevation of soluble form
of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease, Diabetes Metab Res
Rev 23(5), 2007, 368–371.
[10] Position statement, Standards of Medical Care in Diabetes—2012, Diabetes Care, 35 (1), 2012, S11-S63.